Last reviewed · How we verify
Sulfamerazin (SULFAMERAZINE)
Sulfamerazine works by inhibiting the synthesis of folic acid in bacteria, which is essential for their growth and replication.
Sulfamerazine is a sulfonamide antibiotic small molecule developed by Lederle, which was FDA approved in 1949. It belongs to the sulfonamide class of drugs but its target is unknown. Sulfamerazine is used to treat various bacterial infections, although its specific indications are not provided. The commercial status of sulfamerazine is unclear, as it is owned by Lederle but its patent status is unknown. Key safety considerations include its bioavailability of 81%, but its half-life and generic manufacturers are unknown.
At a glance
| Generic name | SULFAMERAZINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | sulfamerazine |
| Target | Dihydropteroate synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1949 |
Mechanism of action
Imagine your body's cells are like factories that need a special ingredient called folic acid to make more cells. Sulfamerazine blocks the bacteria's ability to make this ingredient, so they can't grow and multiply. This helps your body fight off the infection.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfamerazin CI brief — competitive landscape report
- Sulfamerazin updates RSS · CI watch RSS
- Pfizer portfolio CI